All funding opportunities posted each Monday in the RCA Update are archived here.
The Biomedical Advanced Research and Development Authority (BARDA) is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA). Specifically, BARDA is pursuing the following products or technologies: Diagnostic assays for human pan-coronaviruses; Point-of-Care diagnostic assays for SARS-CoV-2 virus; Diagnostic assay to detect COVID-19 disease; Vaccines for novel coronavirus; Therapeutics for novel coronavirus; Ventilators; Immunomodulators or therapeutics targeting lung repair; Pre-exposure and post-exposure prophylaxis for novel coronavirus exposure; Respiratory protective devices; and Advanced Manufacturing Technologies.
The purpose of this Funding Opportunity Announcement (FOA) (PA-20-172) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories.
Standard dates apply.The first standard due date for this FOA is October 5, 2020.
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). The National Institute of Allergy and Infectious Diseases (NIAID) is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
Applications will be accepted on a rolling basis.
The NIH National Institute of Allergy and Infectious Diseases (NIAID) is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.
In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications to address the following research areas of interest:
- Studies to identify optimal in vitro culture requirements and conditions;
- Development of reagents and assays for virus characterization;
- Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
- Studies to identify viral epitopes critical for binding neutralization;
- Studies to examine virus stability and persistence;
- Production of molecular clones of SARS-CoV-2, reporter viruses and recombinant viral proteins;
- Development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;
- Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence;
- Virologic and serologic surveillance studies of the distribution and natural history of SARS-CoV-2 viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;
- Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2;
- Development of SARS-COV-2 therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of SARS-CoV-2 antiviral activity of existing or candidate therapeutics initially developed for other indications;
- Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and
- Development of SARS-CoV-2 vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice:
- PA-19-052 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-19-053 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional)
- PA-19-056 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-19-272 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- PA-19-270 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
The National Institute of Environmental Health Sciences (NIEHS) encourages applications for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. To apply, you can use several mechanisms:
- For a new R21 grant that doesn’t build off an existing NIEHS grant, apply to RFA-ES-19-011 (Time-Sensitive Research Opportunities in Environmental Health Sciences) providing the time-sensitive criteria are met. (The entire cycle from submission to award is expected to be 3 – 4 months.)
- For a supplement to a current funded NIEHS grant within your scope of work, apply to PA-18-591 (Administrative Supplement)
- For a work related to a current funded NIEHS grant, but outside the original scope of work, apply to PA-18-935 (Urgent Competitive Revision)
The National Library of Medicine (NLM) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for innovative high-risk / high impact research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NLM’s strategic goal of fostering data driven research. In order to rapidly improve understanding of the infection of SARS-CoV-2 and of COVID-19, NLM is encouraging the submission of R21 applications to address the following research areas of interest:
- Methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, or other relevant topics such as discovery of risks for infection by SARS-Cov-2 viruses, use of standard terminologies for these viruses in federated health data sets
- Public health surveillance methods that mines genomic, viromic, health data, environmental data and/or data from other pertinent sources such as social media, to identify spread and impact of SARS-Cov-2
Applications are expected to focus on informatics and data science methods to help address the COVID-19 pandemic in a timely manner. Applications that are not responsive will be withdrawn without review.
Deadline: June 16, 2020
The National Institute of Minority Health and Health Disparities (NIMHD), with the other participating NIH Institutes, Centers, and Offices (ICOs),intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit research to evaluate community interventions testing
- the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and
- already implemented, new, or adapted interventions to address the adverse psychosocial, sociocultural, behavioral, and socioeconomic consequences of the pandemic on the health of these groups.
This FOA will utilize the R01 activity code. Researchers will be encouraged to partner with community organizations, health service providers, public health agencies, policymakers, and other stakeholders to prepare and submit applications. This notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications. The FOA is expected to be published in June 2020 with an expected application due date in July 2020.
The National Institute of Mental Health (NIMH) with other Institutes and Centers are issuing this Notice of Intent to Publish a Funding Opportunity Announcement (FOA) to promote new initiatives that will solicit applications to support research to determine the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), wearable devices] to address secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic, particularly among populations who experience health disparities and vulnerable populations.
This FOA will utilize the R01 activity code and academic researchers will be required to partner with digital health developers and/or existing well-established digital health delivery platforms to prepare and submit applications. This notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications. The FOA is expected to be published in June 2020 with an expected application due date in July 2020.
The recently signed Coronavirus Aid, Relief, and Economic Security Act (CARES Act) included $75M for the National Science Foundation (NSF) in support of the agency’s ongoing RAPID grant response. Research can explore how to model and understand the spread of COVID-19; to inform and educate about the science of virus transmission and prevention; and to encourage the development of processes and actions to address this global challenge.
NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, researchers are invited to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration.
All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to firstname.lastname@example.org.
Complete guidance on submitting a RAPID proposal may be found in Chapter II.E.1 of the NSF Proposal and Award Policies and Procedures Guide.
For additional information:
- NSF Dear Colleague Letter on the Coronavirus Disease (20-052)
- Frequently Asked Questions for NSF DCL 20-052
NSF has encouraged submission of proposals related to Coronavirus Disease 2019 (COVID-19), as described in a previous Dear Colleague Letter. The Division of Undergraduate Education (DUE) is specifically interested in research on the impact of the COVID-19 outbreak on undergraduate education. The outbreak has altered undergraduate education in unforeseen ways, including forcing temporary closures and unplanned switches to online classes. DUE thinks that research about the impacts of such responses on students and educators could provide important new knowledge about STEM learning, virtual learning environments, the impact of stress on learning, and many other important topics.
If you are engaged in such research or would like to do so, you are encouraged to consider submitting a proposal to any of our relevant funding programs, including the Improving Undergraduate STEM Education (IUSE): EHR program, the IUSE:HSI program, the S-STEM program, the ATE program, the Noyce Program, and the ECR Core research program.
Alternatively (or in addition), if you have an urgent research need or opportunity, you may consider submitting proposals via the following funding mechanisms:
- Submit a Rapid Response Research (RAPID) proposal.
See Chapter II.E.1 of the NSF Proposal and Award Policies and Procedures Guide
- Request supplemental support for your existing award.
See Chapter VI.E.4 of the NSF Proposal and Award Policies and Procedures Guide
- Organize a conference or workshop.
See Chapter II.E.7 of the NSF Proposal and Award Policies and Procedures Guide
Possible topics of interest for these funding mechanisms include, but are not limited to, research on the effectiveness of switching from an in-person to a completely online educational format and research on how the outbreak affects student attitudes, interests, and performance in STEM.
Important: You should contact a program officer to explore whether your needs might be appropriate for funding via the RAPID, Supplemental Support, or Conference mechanisms. A list of DUE staff is available at https://www.nsf.gov/staff/staff_list.jsp?org=DUE&from_org=DUE.